The Ortho Show
The Ortho Show was born from a passion to share remarkable, insightful, educational and just plain entertaining stories from the world of orthopedics.
Benjamin Young
Over my many years working in the medical device sector I’ve had the good fortune to work with some of the industry’s most respected orthopedic surgeons. I’m excited to use The Ortho Show to share the amazing stories of some of my friends and colleagues I’ve met along the way. I genuinely hope you enjoy it and find something of value within these episodes.
Micah Nicholls
Prior to my involvement in orthopedics, I worked first as an electronic engineer in Silicon Valley and then, after retraining in the UK, as an osteopath. For the past 11 years I’ve been doing research in orthopedics both in academia and for industry. I look forward to bringing you conversations with some of the great minds I’ve had the pleasure of meeting during this time.
Theme music by Kevin Pollard
Episodes
Hosted by Dr. Scott Sigman – “Dr. Arun Hariharan”
Dr. Arun R. Hariharan is a fellowship-trained pediatric orthopedic surgeon with particular expertise in pediatric spine surgery. His main passions are in caring for children with spine-related problems such as scoliosis from a variety of conditions.
Topics include:
-Dr. Hariharan has a true passion for spine and refining his skills for pediatrics. We hear about his desire and pathway to becoming a pediatric orthopedic surgeon.
-He discusses his gratification of helping pediatrics patients and the ability to care for children with goals to get better without secondary gain. It’s interesting to hear about the differences between kids and adults with orthopedic issues. Kids just want to be fixed and go home.
-Dr. Hariharan provides advice for young orthopedic surgeons who are choosing their specialty.
Find out more about Dr. Arun Hariharan here.
Hosted by Dr. Scott Sigman – “Dr. Alexander Sah”
This episode is brought to you by Heron Therapeutics. Please see full Prescribing Information, including Boxed Warning or visit www.ZYNRELEF.com.
Dr. Alexander Sah joins for this episode from Sah Orthopaedic Associates at theInstitute for Joint Restoration in Fremont, CA. He is an orthopedic surgeon, specializing in minimally invasivehip and knee replacements,knee arthroscopy, as well as complex hip and knee revision surgeries.
Topics include:
-We hear about his patient-first emphasis with thorough and compassionate care. He has a deep commitment to the Bay Area community going home to practice at the same hospital he was born, Washington Hospital.
-We discuss his family influence in becoming a physician with his uncles, grandfather, and father practicing medicine. He completed his orthopedic training at Harvard in Boston and specialized fellowship training in minimally invasive and revision hip and knee surgery at Rush University in Chicago.
-Dr. Sah has built his brand with minimally invasive surgery where patients seek him out as a destination practice at Sah Orthopaedic Associates.
-We talk ambulatory surgery centers (ASCs) and answer these questions: Is it safe? Is it cost effective? What is the patient satisfaction?
-Dr. Sah discusses his interest in orthopedic research and remains active in publishing articles and presenting this work at national meetings. He worked with Heron Therapeutics as an expert in total knee replacement as the company developed the pivotal clinical study program to help inform FDA submissions and meet FDA guidelines for ZYNRELEF. ZYNRELEF utilizes a novel synergistic mechanism of action that combines bupivacaine with a low dose of meloxicam to overcome the challenges of the inflammatory process at the surgical site. ZYNRELEF is the first and only extended-release dual-acting local anesthetic (DALA) and delivers 72 hours of postoperative pain relief via a single needle-free application. It has been clinically proven to better manage pain than standard of care bupivacaine HCl solution over 72 hours and to significantly reduce opioid utilization following surgery.
-ZYNRELEF was initially approved by the FDA in May 2021 and in December 2021, the FDA approved an expansion of ZYNRELEF’s indication.
-Limitations of Use: Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large multilevel spinal, and head and neck procedures.
WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS
See full prescribing information for complete boxed warning.
• Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use
• ZYNRELEF is contraindicated in the setting of coronary artery bypass graft (CABG) surgery
• NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events
ZYNRELEF is contraindicated for:
• Patients with a known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to any local anesthetic agent of the amide-type, NSAIDs, or to any of the other components of ZYNRELEF OR history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients
• Patients undergoing obstetrical paracervical block anesthesia OR coronary artery bypass graft (CABG) surgery
WARNINGS AND PRECAUTIONS include –
Cardiovascular (CV) Thrombotic Events with NSAID Use; Gastrointestinal Bleeding, Ulceration, and Perforation with NSAID Use; Dose-Related Toxicity; Risk of Use in Patients with Impaired Cardiovascular Function; Hepatotoxicity; Hypertension; Heart Failure and Edema; Renal Toxicity and Hyperkalemia; Anaphylactic Reactions; Chondrolysis; Methemoglobinemia; Exacerbation of Asthma Related to Aspirin Sensitivity; Serious Skin Reactions; Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS); Hematologic Toxicity; Masking of Inflammation and Fever.
Find out more about Dr. Alexander Sah here.
Hosted by Dr. Scott Sigman – “Dr. Atiba Jackson”
This episode is brought to you by Heron Therapeutics. Please see full Prescribing Information, including Boxed Warning or visit www.ZYNRELEF.com.
If you like happy vibes with a positive patient track record, we’ve got the orthopedic surgeon for you. Meet Dr. Atiba Jackson from Dayton, OH. He is a Board-Certified Orthopedic Sports Medicine specialist, with fellowship training in sports medicine so he can provide the highest level of care for this brand of injuries. He treats complex shoulder injuries including rotator cuff, labrum, SLAP tears, instability, and dislocations. In addition to treating difficult knee injuries, including ACL tears, ligamentous injuries, meniscus tears, cartilage injuries, he also treats elbow injuries and performs elbow arthroscopy. He cares for arthritis patients, performing replacements of the shoulder, knee, and hip.
Topics include:
-His family influence in becoming an orthopedic surgeon, as his father is a family practice doctor. Dr. Jackson has strong family ties and we hear the importance of family in this episode. He also became a teenage parent, overcame the adversity and remained focused on becoming an orthopedic surgeon.
-Dr. Atiba Jackson helps train the clinical and surgical techniques at the Grandview Orthopedic Residency (DO) program. We hear about the post-grant research position they’ve developed for those in a bridge year to help them become more of a competitive applicant.
-He has social media following for promoting his private practice, Orthopedic Associates, and educating his patients. Dr. Jackson looks like Usher and uses it to his advantage when creating engaging posts.
Find out more about Dr. Atiba Jackson here.
Also, find out more about Zynrelef here:
ZYNRELEF utilizes a novel synergistic mechanism of action that combines bupivacaine with a low dose of meloxicam to overcome the challenges of the inflammatory process at the surgical site. ZYNRELEF is the first and only extended-release dual-acting local anesthetic (DALA) and delivers 72 hours of postoperative pain relief via a single needle-free application. It has been clinically proven to better manage pain than standard of care bupivacaine HCl solution over 72 hours and to significantly reduce opioid utilization following surgery.
-ZYNRELEF was initially approved by the FDA in May 2021 and in December 2021, the FDA approved an expansion of ZYNRELEF’s indication.
-Limitations of Use: Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large multilevel spinal, and head and neck procedures.
WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS
See full prescribing information for complete boxed warning.
• Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use
• ZYNRELEF is contraindicated in the setting of coronary artery bypass graft (CABG) surgery
• NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events
ZYNRELEF is contraindicated for:
• Patients with a known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to any local anesthetic agent of the amide-type, NSAIDs, or to any of the other components of ZYNRELEF OR history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients
• Patients undergoing obstetrical paracervical block anesthesia OR coronary artery bypass graft (CABG) surgery
WARNINGS AND PRECAUTIONS include –
Cardiovascular (CV) Thrombotic Events with NSAID Use; Gastrointestinal Bleeding, Ulceration, and Perforation with NSAID Use; Dose-Related Toxicity; Risk of Use in Patients with Impaired Cardiovascular Function; Hepatotoxicity; Hypertension; Heart Failure and Edema; Renal Toxicity and Hyperkalemia; Anaphylactic Reactions; Chondrolysis; Methemoglobinemia; Exacerbation of Asthma Related to Aspirin Sensitivity; Serious Skin Reactions; Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS); Hematologic Toxicity; Masking of Inflammation and Fever.
Hosted by Dr. Scott Sigman – “Andrew Ittleman”
We have an educational episode and slight pivot on the fringe of orthopedics this week with attorney Andrew Ittleman. He is a Founder and Partner of Fuerst Ittleman David & Joseph. He concentrates his practice in the areas of White Collar Criminal Defense, Anti-Money Laundering Compliance and Food and Drug Law. Mr. Ittleman litigates extensively against the United States government in civil and criminal matters. He is an expert in explaining on what is/isn’t kosher is the space of orthobiologics and what is on/off label.
Topics include:
-We discuss stem cell procedures and what you can/can’t say in marketing claims.
-Tune-in to hear a thorough discussion on the status of Platelet Rich Plasma (PRP) and the meaning of on/off labeling.
-Advice for orthopedic surgeons using orthobiologics. If you’re going to do it, be transparent, be careful with marketing claims, and use appropriate claims and testimonials.
-Andrew gives sage advice for patients considering these treatments.
Find out more about Andrew Ittleman here.
Hosted by Dr. Scott Sigman – “Dr. Anand Murthi”
This episode is brought to you byModMed.To learn more and see a demo of the #1 EHR system, EMA®, as well as Practice Management, Revenue Cycle Management, Analytics, Patient Engagement tools and more, visitmodmed.com/orthopod.ModMed— it’s abouttime.
Dr. Anand Murthi is the Chief, Shoulder and Elbow Surgery, at MedStar Union Memorial Hospital, where he also serves as the Director of the Shoulder and Elbow Fellowship and Research. He is a board-certified orthopaedic surgeon, fellowship trained in shoulder and elbow surgery, who sees patients in Timonium (Baltimore County) and in Baltimore at MedStar Union Memorial.
Topics include:
-Dr. Murthi completed the internationally recognized fellowship in shoulder and elbow reconstruction at the New York Orthopaedic Hospital-Columbia Presbyterian Medical Center. He discusses the influence and importance of mentorship.
-He is also an elected member of the prestigious American Shoulder and Elbow Surgeons Society (ASES), an international group of shoulder and elbow surgeons dedicated to the mission of teaching and research for which he has chaired the Education Committee.
–Dr. Murthi has published and presented numerous research papers on a national and international stage. He has a passion for research, including fragility index (FI) studies. The fragility index (FI) is a method used with statistically significant dichotomous outcomes to assess the number of patients that would change an outcome measure from significant (P≤ .05) to nonsignificant if the patient outcome changed.
-He is also passionate about medical device design and part of the explosion of innovation in shoulder replacements. Dr. Murthi discusses some of the innovations he’s worked on.
-He is also a part of the team to develop the first international shoulder data registry (Shoulder JAM by OBERD).
Find out more about Dr. Anand Murthi here.
Hosted by Dr. Scott Sigman – “Dr. Robert Masson”
This episode is brought to you byModMed.To learn more and see a demo of the #1 EHR system, EMA®, as well as Practice Management, Revenue Cycle Management, Analytics, Patient Engagement tools and more, visitmodmed.com/orthopod.ModMed— it’s abouttime.
When Matthew Ray Scott says this is the most interesting surgeon in the world, we have them on The Ortho Show. For the episode, we have spine surgeon Dr. Robert L. Masson, M.D., an internationally recognized neurosurgeon specializing in minimally invasive spine surgery and sports spine medicine. As the founder of the Masson Spine Institute, he serves as Medical Director of the Orlando Health Health Central Central Hospital JCAHO accredited Spine Center of Excellence in West Orlando.
Dr. Masson performs surgery at the Masson Spine Institute (MSI) Outpatient Surgery Centers of Excellence in both Orlando, Florida and Park City, Utah, where patients and surgeons travel from all over the world for advanced micro-surgical spine surgery strategies, solutions, techniques, and training.
Topics include:
-Dr. Masson is our first neurosurgeon on The Ortho Show. He is a master marketer who developed a brand that attracts patients to him in a destination center as a sports spine surgeon.
-We discuss how he was inspired to open the Masson Spine Institute to serve his community and how it was a team effort with getting the center’s to where they are today.
-We hear about Dr. Masson’s holistic 360-degree approach with his patients regarding the entire continuum of spine care.
-Dr. Masson is the proud father of five, and has been married for 30 years. His family celebrates athletics and adventure sports, including as an accomplished prototype racer, finishing second place, along with his son, professional racer Kyle Masson in the 2019 Rolex 24 Hours at Daytona with Performance Tech Motorsports. Dr. Masson also climbed Mount Kilimanjaro in 2014.
Find out more about Dr. Robert Masson here.
Responses